Here’s a Heartwarming Story of Innovation in the Pharmaceutical Business

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


Apparently the new hotness in the pharmaceutical industry is this: (1) Find an old, generic drug that’s used only rarely and made by only one company. (2) Buy it. (3) Jack up the price astronomically. Since you have a monopoly, there’s not much that anyone can do about it. And since it’s a rarely used drug, it’s not really worth anyone’s time to manufacture a competing version.

At the New York Times, Andrew Pollack spotlights this problem with the story of Daraprim, which was acquired last month by an ex-hedge fund manager who immediately raised the price from $13.50 per tablet to $750 per tablet. He offered up two excuses for doing this:

Daraprim, known generically as pyrimethamine, is used mainly to treat toxoplasmosis, a parasite infection that can cause serious or even life-threatening problems for babies born to women who become infected during pregnancy, and also for people with compromised immune systems, like AIDS patients and certain cancer patients.

Martin Shkreli, the founder and chief executive of Turing, said that the drug is so rarely used that the impact on the health system would be minuscule and that Turing would use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Mr. Shkreli said. He said that many patients use the drug for far less than a year and that the price was now more in line with those of other drugs for rare diseases.

“This is still one of the smallest pharmaceutical products in the world,” he said. “It really doesn’t make sense to get any criticism for this.”

….Turing’s price increase could bring sales to tens or even hundreds of millions of dollars a year if use remains constant.

So there you have it. It’s such a tiny market that, really, who cares? Chill, people. And anyway, they’re going to use their newly found profits to develop wonderful new treatments for toxoplasmosis. I wouldn’t hold my breath for that to happen. Besides, doctors who use the drug say that Daraprim works fine and no one’s really clamoring for something better.

Welcome to the 21st century pharmaceutical biz, working hard to find new and innovative ways of gouging the most vulnerable members of society. And for once, we can truly say that this could happen only in America, since no other country would allow it. Makes you proud, doesn’t it?

WE'LL BE BLUNT:

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't find elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

WE'LL BE BLUNT

We need to start raising significantly more in donations from our online community of readers, especially from those who read Mother Jones regularly but have never decided to pitch in because you figured others always will. We also need long-time and new donors, everyone, to keep showing up for us.

In "It's Not a Crisis. This Is the New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, how brutal it is to sustain quality journalism right now, what makes Mother Jones different than most of the news out there, and why support from readers is the only thing that keeps us going. Despite the challenges, we're optimistic we can increase the share of online readers who decide to donate—starting with hitting an ambitious $300,000 goal in just three weeks to make sure we can finish our fiscal year break-even in the coming months.

Please learn more about how Mother Jones works and our 47-year history of doing nonprofit journalism that you don't elsewhere—and help us do it with a donation if you can. We've already cut expenses and hitting our online goal is critical right now.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate